Status:
COMPLETED
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of COPD and a history of cigarette smoking.
- Exclusion criteria:
- Significant heart or lung disease not associated with COPD.
- Significant stomach or intestinal disease.
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00103922
Start Date
November 1 2004
End Date
January 1 2007
Last Update
October 28 2016
Active Locations (115)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35209
2
GSK Investigational Site
Jasper, Alabama, United States, 35501
3
GSK Investigational Site
Phoenix, Arizona, United States, 85006
4
GSK Investigational Site
Tempe, Arizona, United States, 85282